Ilyang Pharm (007570) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.009x

Based on the latest financial reports, Ilyang Pharm (007570) has a cash flow conversion efficiency ratio of 0.009x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩239.41 Billion ≈ $162.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Ilyang Pharm - Cash Flow Conversion Efficiency Trend (2003–2024)

This chart illustrates how Ilyang Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Ilyang Pharm carry for a breakdown of total debt and financial obligations.

Ilyang Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilyang Pharm ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Oando PLC JSE:OAO	-0.158x
Scandinavian Astor Group AB ST:ASTOR	0.042x
Habco Trans Maritima JK:HATM	0.017x
Byggma OL:BMA	-0.001x
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. IS:ONCSM	0.126x
Muhak Co. Ltd KO:033920	-0.009x
Acme United Corporation NYSE MKT:ACU	0.071x
Buligo Capital Ltd TA:BLGO	0.081x

Annual Cash Flow Conversion Efficiency for Ilyang Pharm (2003–2024)

The table below shows the annual cash flow conversion efficiency of Ilyang Pharm from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see Ilyang Pharm stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩241.58 Billion ≈ $163.71 Million	₩5.61 Billion ≈ $3.81 Million	0.023x	-65.79%
2023-12-31	₩196.41 Billion ≈ $133.10 Million	₩13.34 Billion ≈ $9.04 Million	0.068x	-33.76%
2022-12-31	₩291.85 Billion ≈ $197.79 Million	₩29.94 Billion ≈ $20.29 Million	0.103x	-58.41%
2021-12-31	₩271.76 Billion ≈ $184.17 Million	₩67.02 Billion ≈ $45.42 Million	0.247x	+5.08%
2020-12-31	₩244.92 Billion ≈ $165.98 Million	₩57.48 Billion ≈ $38.96 Million	0.235x	+44.44%
2019-12-31	₩222.74 Billion ≈ $150.95 Million	₩36.19 Billion ≈ $24.53 Million	0.162x	+54.17%
2018-12-31	₩209.88 Billion ≈ $142.23 Million	₩22.12 Billion ≈ $14.99 Million	0.105x	-25.94%
2017-12-31	₩210.98 Billion ≈ $142.98 Million	₩30.03 Billion ≈ $20.35 Million	0.142x	+14.64%
2016-12-31	₩217.35 Billion ≈ $147.30 Million	₩26.98 Billion ≈ $18.29 Million	0.124x	-34.96%
2015-12-31	₩211.00 Billion ≈ $142.99 Million	₩40.27 Billion ≈ $27.29 Million	0.191x	+87.97%
2014-12-31	₩183.46 Billion ≈ $124.33 Million	₩18.63 Billion ≈ $12.62 Million	0.102x	+714.91%
2013-12-31	₩183.88 Billion ≈ $124.61 Million	₩-3.04 Billion ≈ $-2.06 Million	-0.017x	-112.63%
2003-12-31	₩77.13 Billion ≈ $52.27 Million	₩10.08 Billion ≈ $6.83 Million	0.131x	--

About Ilyang Pharm

KO:007570 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$158.52 Million

₩233.92 Billion KRW

Market Cap Rank

#17432 Global

#807 in Korea

Share Price

₩13050.00

Change (1 day)

+0.00%

52-Week Range

₩12300.00 - ₩15130.00

All Time High

₩95982.23